Get started
Author

Michael Zoerer

Observed name: Michael Zörer
OpenAlex ID: A5014908415
Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial
2018 · Martin Unger, Andrea Morelli, et al. · Trials · 22
PDF
Germline genetic factors influence the outcome of interferon-α therapy in polycythemia vera
2020 · Roland Jäger, Heinz Gisslinger, et al. · Blood · 19
Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results
2018 · Heinz Gisslinger, Veronika Buxhofer-Ausch, et al. · Blood · 18
Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study
2013 · Heinz Gisslinger, Veronika Buxhofer-Ausch, et al. · Blood · 9
AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)
2012 · Heinz Gisslinger, Robert Kralovics, et al. · Blood · 5
Safety and Efficacy Profile of rAHF-PFM for Immune Tolerance Induction as Assessed In 3 Clinical Trials (PUP ITI, PRE-PAIR, and PAIR).
2010 · Gerald Spotts, Brigitt E. Abbuehl, et al. · Blood · 2
Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud
2015 · Veronika Buxhofer-Ausch, Heinz Gisslinger, et al. · Blood · 1
Vmx-C001 has no effect on the anticoagulant function of heparin in healthy subjects
2025 · Gerard Short, Michael Zörer, et al. · Blood
PDF
Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera
2019 · Roland Jäger, Elisabeth Fuchs, et al. · Blood
Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient
2015 · Heinz Gisslinger, Veronika Buxhofer-Ausch, et al. · Blood
Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study
2014 · Heinz Gisslinger, Veronika Buxhofer-Ausch, et al. · Blood
Works count: 11
Citation count: 76
H-index: 5
I10-index: 3
Year
Topic
Type